Gloria G Guerrero M¹*, Arturo Araujo Conejo², Enciso-De la Torre Andrés¹, Diana Cecilia Reyes-Moreno³, Diego Cano-Sanchez⁴ and Paulina Perez-Maldonado^5,6

¹Unidad Académica de Ciencias Biológicas, Universidad Autónoma de Zacatecas, Campus II, Av. Preparatoria S/N. Col Agronómicas, ZP, 98066, Zacatecas, Zac, MEX, Mexico
²Hospital General Zacatecas "Luz González Cosió" de la Secretaria de Salud de Zacatecas, Zacatecas, Zacatecas, Zac, MEX, Mexico
³Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Campus Siglo XXI, Mexico
⁴Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Campus Fresnillo, Zac, MEX, Mexico
⁵Programa de Licenciatura en Biología, Unidad Académica de Ciencias Biológicas, Universidad Autónoma de Zacatecas, Zacatecas, Zac, MEX, Mexico
⁶Centro de Salud El Bordo, Secretaria de Salud de Zacatecas, Zacatecas, Zac, MX, Mexico

*Corresponding Author: Gloria G Guerrero M, Unidad Académica de Ciencias Biológicas, Universidad Autónoma de Zacatecas, Campus II, Av. Preparatoria S/N. Col Agronómicas, ZP, 98066, Zacatecas, Zac, MEX, Mexico.

Received: February 24, 2024; Published: April 08, 2024

Abstract

Cancer is one of the most common causes of death, with up to 14 million worldwide. The oncogenic therapies and immunotherapies against the diverse forms of cancer remain to be defined. Radio and Chemotherapy are still the anti-cancer of the first choice. However, the secondary effects of these treatments are detrimental to the health. Several studies have reported the pro-apoptotic properties of HAMLET (Human alpha-lactalbumin Made Lethal to Tumor cells). The hypothesis is that complex formation with fatty acids cause membrane disruption of the cancerous cells. Therefore, in the present study, we aimed to evaluate the oral administration of Hamlet in case control study. The microbial growth in stool samples of the individual treated with HAMLET at four different time points during two weeks were recording in selective medium (MC, Trypt, EMB, and BA) for Firm cutes and Bacteroidetes (90%) and for the rest 10% of mostly Gram negative), among them the Proteobacteria (of utmost of the family Enterobacteriaceae). Antibiotics sensibility and resistance, Gram staining and Colony-forming (CFUs) evaluated at different time points of the HAMLET treatment. Altogether, the data show a modulation of the composition and behavior of the gut microbiota in the treated than untreated individual. In EMB selectively grew in higher amount both types of colonies. From the results we suggest that the positive effect of the oral administration of HAMLET might be beneficial for patients before surgery and or radio/chemotherapeutic treatment.

Keywords: Hamlet; Cancer; Radiation Therapy

References

1. World Health Organization (WHO). “World health statistics 2022: monitoring health for the SDGs, sustainable development goals” (2022).
2. Hanahan D and Weinberg RA. “Hallmarks of cancer: the next generation”. Cell 144 (2011): 646-674.
3. Brucher BLDM and Jamall IS. “Somatic mutation theory: Why it’s wrong for most cancers”. Cell Cellular Physiology and Biochemistry 38 (2016): 1663-1680.
4. Hull D 3d., et al. “Multiple estrogen receptor assays in human breast cancer”. Cancer Research 42 (1983): 413-416.
5. Djahansouzi S., et al. “The rate of estrogen receptor-conversion associated with tumor progression in estrogen receptor-positive breast cancer patients following adjuvant Tamoxifen administration”. Cancer Reports (Hoboken) 5 (2022): e1431.
6. Qiao M., et al. “Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis”. c Molecular Cell 38 (2010): 512-523.
7. Røsland GV and Engelsen AST. Novel points of attack for targeted cancer therapy”. Basic and Clinical Pharmacology and Toxicology 116 (2015): 9-18.
8. De Palma M and Hanahan D. “The biology of personalized cancer medicine: facing individual”. Molecular Oncology 6 (2012): 111-127.
9. DeVita VT and Chu E. “A history of cancer chemotherapy”. Cancer Research 68 (2008): 8643-8653.
10. Achilli P., et al. “Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the national cancer database”. International Journal of Cancer 148 (2021): 161-169.
11. Chabner BA and Roberts TG. “Timeline: chemotherapy and the war on cancer”. Nature Reviews Cancer 5 (2005): 65-72.
12. Duan S and Buxton ILO. “Evolution of Medical Approaches and Prominent Therapies in Breast Cancer”. Cancers (Basel) 14 (2022): 2450.
13. Martin OA and Martin RF. “Cancer radiotherapy: understanding the price of tumor eradication”. Frontiers in Cell and Developmental Biology 8 (2020): 261.
14. Lee S and Margolin K. “Cytokines in cancer immunotherapy”. Cancers (Basel) 3 (2011): 3856-3893.
15. Rosenstock AS., et al. “Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients”. Cancer 124 (2018): 899-906.
16. van Hagen P., et al. “CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer”. The New England Journal of Medicine 366 (2012): 2074-2084.
17. Ndagi U., et al. “Metal complexes in cancer therapy - an update from drug design perspective”. Drug Design, Development and Therapy 11 (2017): 599-616.
18. Fraguas-Sánchez AI and Torres-Suárez AI. “Medical use of cannabinoids”. Drugs 78 (2018): 1665-1703.
19. Rosenberg SA., et al. “A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone”. The New England Journal of Medicine 316 (1987): 889-897.
20. Kataoka M., et al. “Structural characterization of the molten globule of α-lactalbumin by solution X-ray scattering”. Protein Science 6 (1997): 422-430.
21. Permyakov EA. “Alpha-lactalbumin, amazing calcium-binding protein”. Biomolecules 10 (2020): 1210-1260.
22. Hakansson A., et al. “Apoptosis induced by a human milk protein”. Proceedings of the National Academy of Sciences of the United States of America 92 (1995): 8064-8068.
23. Ho JC., et al. “Svanborg, Targeting of nucleotide-binding proteins by HAMLET-a conserved tumor cell death mechanism”. Oncogene 35 (2016): 897-907.
24. Storm P., et al. “A unifying mechanism for cancer cell death through ion channel activation by Hamlet”. PLoS One 8 (2013): e58578.
25. Pettersson J., et al. “Alpha-lactalbumin species variation, Hamlet formation, and tumor cell death”. Biochemical and Biophysical Research Communications 345 (2006): 260-270.
26. Frislev HS., et al. “Liprotides kill cancer cells by disrupting the plasma membrane”. Scientific Reports 7 (2017): 15129.
27. Frislev HS., et al. “Liprotides made of alpha-LA and cis fatty acids form core-shell and multi-layer structures with a common membrane-targeting mechanism”. Biochimica et Biophysica Acta 1864 (2016): 847-859.
28. Hakansson A., et al. “Multimeric alpha-lactalbumin from human milk induces apoptosis through a direct effect on cell nuclei”. Experimental Cell Research 246 (1999): 451-460.
29. Kohler C., et al. “Protease activation in apoptosis induced by MAL”. Experimental Cell Research 249 (1999): 260-268.v
30. Nakamura T., et al. “Molecular mechanisms of the cytotoxicity of human alpha-lactalbumin made lethal to tumor cells (HAMLET) and other protein-oleic acid complexes”. Journal of Biological Chemistry 288 (2013): 14408-14416.
31. Mossberg AK., et al. “Structure and function of human alpha-lactalbumin made lethal to tumor cells (HAMLET)-type complexes”. FEBS Journal 277 (2010): 4614-4625.
32. Min S., et al. “Alternatively folded proteins with unexpected beneficial functions”. Biochemical Society Transactions 40 (2012): 746-751.
33. Fontana A., et al. “The biological activities of protein/oleic acid complexes reside in the fatty acid”. Biochimica et Biophysica Acta 1834 (2013): 1125-1143.
34. Ho JCS., et al. “HAMLET: Functional properties and therapeutic potential”. Future Oncology 8 (2012): 1301-1313.
35. Ho JCS., et al. “HAMLET-A protein-lipid complex with broad tumoricidal activity”. Biochemical and Biophysical Research Communications 482 (2017): 454-458.
36. Brinkmann CR., et al. “Protein-fatty acid complexes: Biochemistry, biophysics and function”. FEBS Journal 280 (2013): 1733-1749.
37. Lerksuthirat T., et al. “ALA-A2 Is a Novel Anticancer Peptide Inspired by Alpha-Lactalbumin: A Discovery from a Computational Peptide Library, In Silico Anticancer Peptide Screening and In Vitro Experimental Validation”. Global Challenges 7 (2023): 2200213.
38. Brisuda A., et al. “Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex”. Nature Communications 12 (2021): 3427-3443.
39. Pedroza MSH and Lyavoo S. “Exploring the gut microbiota: lifestyle choices, disease associations, and personal genomics”. Frontiers in Nutrition 10 (2023): 1225120.
40. Ley RE., et al. “Ecological and evolutionary forces shaping microbial diversity in the human intestine”. Cells 124 (2006): 837-848.
41. Jandhyala SM., et al. “Role of the normal gut microbiota”. World Journal of Gastroenterology 21 (2015): 8787-803.
42. Rinninella E., et al. “What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases”. Microorganisms 7 (2019): 14.
43. LeBlanc JG., et al. “Bacteria as vitamin suppliers to their host: a gut microbiota perspective”. Current Opinion in Biotechnology 24 (2013): 160-168.
44. Hills RD., et al. “Gut microbiome: profound implications for diet and disease”. Nutrients 11 (2019): 1613.
45. Galland L. “The gut microbiome and the brain”. Journal of Medicinal Food 17 (2014): 1261-1272.
46. Liu J., et al. “Functions of gut microbiota metabolites, current status and future perspectives”. Aging and Disease 13 (2022): 1106-1126.
47. Makki K., et al. “The impact of dietary fiber on gut microbiota in host health and disease”. Cell Host Microbe 23 (2018): 705-715.
48. Ridlon JM., et al. “Bile acids and the gut microbiome”. Current Opinion in Gastroenterology 30 (2014): 332-338.
49. Pellegrini A. “Antimicrobial peptides from food proteins”. Current Pharmaceutical Design 9 (2003): 1225-1238.
50. Sipola M., et al. “Nurminen ML.alpha-Lactorphin and _-lactorphin improve arterial function in spontaneously hypertensive rats”. Life Sciences 71 (2002): 1245-1253.
51. Kanda Y., et al. “Growth-active peptides are produced from alpha-lactalbumin and lysozyme”. Life Sciences 81 (2007): 449-457.
52. Clare DA., et al. “Biodefense properties of milk: The role of antimicrobial proteins and peptides”. Current Pharmaceutical Design 9 (2003): 1239-1255.
53. Yamaguchi M., et al. “Novel functions of bovine milk-derived alpha-lactalbumin: Anti-nociceptive and anti-inflammatory activity caused by inhibiting cyclooxygenase-2 and phospholipase A2”. Biological and Pharmaceutical Bulletin 32 (2009): 366-371.
54. Fukawa A., et al. “Dietary alpha-lactalbumin protects against thioacetamide-induced liver cirrhosis by maintaining gut-liver axis function in rats”. Bioscience, Biotechnology, and Biochemistry 84 (2020): 171-177.
55. Lin IC., et al. “Induction of cell death in RAW 264.7 cells by _-lactalbumin”. Food and Chemical Toxicology 46 (2008): 842-853.
56. Xu M., et al. “IEC-6 intestinal cell death induced by bovine milkalpha-lactalbumin”. Bioscience, Biotechnology, and Biochemistry 69 (2005): 1082-1089.
57. Yarramala DS., et al. “Cytotoxicity of apo bovine alpha-lactalbumin complexed with La”. Scientific Reports 9 (2019): 1780.
58. Zhang M., et al. “Cytotoxic aggregates of alpha lactalbumin induced by unsaturated fatty acid induce apoptosis in tumor cells”. Chemico-Biological Interactions 180 (2009): 131-142.
59. Brest P., et al. “Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET”. Cancer Research 67 (2007): 11327-11334.
60. El Karim IA., et al. “Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites”. Journal of Neuroimmunology 200 (2008): 11-16.
61. Panduro A., et al. “Genes, emotions and gut microbiota: the next frontier for the gastroenterologist”. World Journal of Gastroenterology 23 (2017): 3030-3042.
62. Neufeld KM., et al. “Effects of intestinal microbiota on anxiety-like behavior”. Communicative and Integrative Biology 4 (2011): 492-494.
63. Carabotti M., et al. “The gut-brain axis: interaction between enteric microbiota, central and enteric nervous systems”. Annals of Gastroenterology 28 (2015): 203-209.
64. Stilling RM., et al. “Microbial genes, brain & behaviour - epigenetic regulation of the gut-brain axis”. Genes, Brain and Behavior 13 (2014): 69-86.
65. O'Riordan KJ., et al. “Short chain fatty acids: microbial metabolites for gut-brain axis signalling”. Molecular and Cellular Endocrinology 546 (2022): 111572.

Citation

Citation: Gloria G Guerrero M., et al. “Prophylactic Effect in the Gut Microbiota After Oral Administration of HAMLET: Results of a Case Control Study".Acta Scientific Microbiology 7.5 (2024): 12-26.

Copyright

Copyright: © 2024 Gloria G Guerrero M., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.